BeiGene(BGNE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BGNE BeiGene

Market Closed 05-10 16:00:00 EDT

161.13

-7.51

-4.45%

盘后161.13

+0.000.00%

19:52 EDT

High166.30	Low161.00	Vol196.40K
Open166.30	D1 Closing168.64	Amplitude3.14%
Mkt Cap16.85B	Tradable Cap9.45B	Total Shares104.58M
T/O31.87M	T/O Rate0.33%	Tradable Shares58.68M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"BGNE","market":"US","secType":"STK","nameCN":"BeiGene","latestPrice":161.13,"timestamp":1715371200000,"preClose":168.64,"halted":0,"volume":196397,"hourTrading":{"tag":"盘后","latestPrice":161.13,"preClose":161.13,"latestTime":"19:52 EDT","volume":585,"amount":94236.31,"timestamp":1715385124063},"delay":0,"floatShares":58678326,"shares":104578797,"eps":-7.519015,"marketStatus":"Market Closed","change":-7.51,"latestTime":"05-10 16:00:00 EDT","open":166.3,"high":166.3,"low":161,"amount":31865886.56677,"amplitude":0.031428,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-7.519015,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1715587200000},"marketStatusCode":7,"adr":1,"adrRate":13,"exchange":"NASDAQ","adjPreClose":168.64,"preHourTrading":{"tag":"盘前","latestPrice":166.71,"preClose":168.64,"latestTime":"09:29 EDT","volume":170,"amount":28386.122300000003,"timestamp":1715347799999},"postHourTrading":{"tag":"盘后","latestPrice":161.13,"preClose":161.13,"latestTime":"19:52 EDT","volume":585,"amount":94236.31,"timestamp":1715385124063},"volumeRatio":1.0401986780926373},"requestUrl":"/m/hq/s/BGNE","defaultTab":"news","newsList":[{"id":"2434300776","title":"BeiGene’s Soaring Sales and Path to Profitability Reinforce Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2434300776","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2434300776?lang=en_us&edition=fundamental","pubTime":"2024-05-10 14:08","pubTimestamp":1715321329,"startTime":"0","endTime":"0","summary":"Analyst Jill Wu from CMB International Securities maintained a Buy rating on BeiGene (BGNE – Research Report) and increased the price target to $26...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/beigenes-soaring-sales-and-path-to-profitability-reinforce-buy-rating?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/beigenes-soaring-sales-and-path-to-profitability-reinforce-buy-rating?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2434400401","title":"Buy Rating Affirmed for BeiGene on Strong Q4 Performance and Promising Brukinsa Sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2434400401","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2434400401?lang=en_us&edition=fundamental","pubTime":"2024-05-10 13:26","pubTimestamp":1715318807,"startTime":"0","endTime":"0","summary":"Leerink Partners analyst Andrew Berens maintained a Buy rating on BeiGene (BGNE – Research Report) on May 8 and set a price target of $267.00. Andr...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/buy-rating-affirmed-for-beigene-on-strong-q4-performance-and-promising-brukinsa-sales?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/buy-rating-affirmed-for-beigene-on-strong-q4-performance-and-promising-brukinsa-sales?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2434098983","title":"BeiGene First Quarter 2024 Earnings: Beats Expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2434098983","media":"Simply Wall St.","top":-1,"share":"https://ttm.financial/m/news/2434098983?lang=en_us&edition=fundamental","pubTime":"2024-05-09 18:32","pubTimestamp":1715250775,"startTime":"0","endTime":"0","summary":"NasdaqGS:BGNE Earnings and Revenue Growth May 9th 2024. All figures shown in the chart above are for the trailing 12 month  period. Revenue exceeded analyst estimates by 9.1%. Earnings per share  also surpassed analyst estimates by 13%.Looking ahead, revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US.The company's shares are up 5.1% from a week ago.Be aware that  BeiGene is showing  1 warning sign in our investment analysis that you should know about...","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/beigene-first-quarter-2024-earnings-103255946.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2434105690","title":"New Risks Emerge for BeiGene: Investors Alerted to Material Updates in Financial Disclosures","url":"https://stock-news.laohu8.com/highlight/detail?id=2434105690","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2434105690?lang=en_us&edition=fundamental","pubTime":"2024-05-09 14:03","pubTimestamp":1715234600,"startTime":"0","endTime":"0","summary":"BeiGene, Ltd. (BGNE) has disclosed a new risk, in the Accounting & Financial Operations category. BeiGene, Ltd. faces new and materially updated ri...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/new-risks-emerge-for-beigene-investors-alerted-to-material-updates-in-financial-disclosures?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/new-risks-emerge-for-beigene-investors-alerted-to-material-updates-in-financial-disclosures?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2434403015","title":"Decoding BeiGene Ltd (BGNE): A Strategic SWOT Insight","url":"https://stock-news.laohu8.com/highlight/detail?id=2434403015","media":"GuruFocus.com","top":-1,"share":"https://ttm.financial/m/news/2434403015?lang=en_us&edition=fundamental","pubTime":"2024-05-09 13:05","pubTimestamp":1715231122,"startTime":"0","endTime":"0","summary":"BeiGene Ltd showcases robust revenue growth with a significant 82% increase in product revenue year-over-year.Research and development expenses continue to rise, reflecting the company's commitment to innovation in oncology.Despite increased revenues, BeiGene Ltd faces a net loss, emphasizing the high costs associated with developing breakthrough cancer treatments.BeiGene Ltd's strategic partnerships and global expansion efforts position it as a key player in the oncology pharmaceutical landscape.GuruFocus has detected 5 Warning Signs with BGNE.Dependence on Third-Party Distributors: BeiGene Ltd's reliance on third-party distributors for the sale of its products introduces a level of risk, as any disruption in the distribution network could adversely affect sal","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/QUqrGh0IDRZl_x4aZ4A6Xg--~B/aD03ODQ7dz0xMjQyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/us.finance.gurufocus/16f223fe020169a3ea149f8fb4171cb1","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/QUqrGh0IDRZl_x4aZ4A6Xg--~B/aD03ODQ7dz0xMjQyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/us.finance.gurufocus/16f223fe020169a3ea149f8fb4171cb1"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/decoding-beigene-ltd-bgne-strategic-050522647.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2433437447","title":"BeiGene Q1 2024 GAAP EPADS $(2.41) Beats $(2.89) Estimate, Sales $751.652M Beat $676.451M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2433437447","media":"Benzinga","top":-1,"share":"https://ttm.financial/m/news/2433437447?lang=en_us&edition=fundamental","pubTime":"2024-05-08 18:10","pubTimestamp":1715163027,"startTime":"0","endTime":"0","summary":"BeiGene (NASDAQ:BGNE) reported quarterly losses of $(2.41) per share which beat the analyst consensus estimate of $(2.89) by 16.61 percent. This is a 27.84 percent increase over losses of $(3.34) per share from the same","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/05/38694178/beigene-q1-2024-gaap-epads-2-41-beats-2-89-estimate-sales-751-652m-beat-676-451m-estimate","is_publish_highlight":false,"gpt_icon":0},{"id":"2433995743","title":"BeiGene Reports First Quarter 2024 Financial Results and Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2433995743","media":"Business Wire","top":-1,"share":"https://ttm.financial/m/news/2433995743?lang=en_us&edition=fundamental","pubTime":"2024-05-08 18:00","pubTimestamp":1715162400,"startTime":"0","endTime":"0","summary":"Total revenues of $752 million in the first quarter, including product revenue of $747 million, an 82% increase from the prior-year period. BRUKINSA revenue of $489 million, driven by growth in the U.S. and Europe of 153% and 243%, respectively, from the prior-year period; with recent fifth FDA approval, BRUKINSA now has the broadest label in the BTKi class. Rapidly advancing late-stage hematology pipeline; sonrotoclax in development both as a monotherapy and in combination with backbone therapy BRUKINSA; pivotal program initiated for BTK CDAC. Progressing potentially differentiated solid tumor programs with ADC, degrader platforms and targeted therapies in priority cancer types. Significantly improved operating leverage and progress on path to sustainable profitability. SAN MATEO, Calif., May 08, 2024----BeiGene, Ltd. , a global oncology company, today announced results from the first quarter 2024 and business highlights.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/YEeDq1qluJ05Zs8gWnLPVw--~B/aD0zMTA7dz0xNjUwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/d56a3d88e3398cd7a1ec661c61234301","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/YEeDq1qluJ05Zs8gWnLPVw--~B/aD0zMTA7dz0xNjUwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/d56a3d88e3398cd7a1ec661c61234301"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/beigene-reports-first-quarter-2024-100000790.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2432326406","title":"BeiGene, AbbVie patent spat to get trial from USPTO appeals board","url":"https://stock-news.laohu8.com/highlight/detail?id=2432326406","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2432326406?lang=en_us&edition=fundamental","pubTime":"2024-05-02 04:12","pubTimestamp":1714594341,"startTime":"0","endTime":"0","summary":"The Patent Trial and Appeal Board of the U.S. Patent and Trademark Office has decided to institute a trial in a patent dispute involving BeiGene  and AbbVie  unit Pharmacyclics. Pharmacyclics has accused BeiGene's Brukinsa  of violating a patent belonging to Imbruvica . Both are BTK inhibitors approved to treat different types of leukemia and lymphoma.  AbbVie , which markets Imbruvica with Johnson & Johnson's  Janssen unit, brought a patent suit against BeiGene  in June 2023 in a Delaware federal court. That lawsuit was filed the same day a key Imbruvica patent was issued. BeiGene filed its appeal request as petitioner with PTAB on Nov. 1, 2023. Pharmacyclics is listed as the respondent. The patent in question, No. 11,672,803, involves the method of use for a BTK inhibitor created under a particular chemical structure for treating chronic lymphocytic leukemia or small lymphocytic lymphoma.","market":"nz","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/899094824/image_899094824.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/899094824/image_899094824.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4097839-beigene-abbvie-patent-spat-get-trial-uspto-appeals-board","is_publish_highlight":false,"gpt_icon":0},{"id":"2430420219","title":"AstraZeneca: Strong In A Weak Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2430420219","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2430420219?lang=en_us&edition=fundamental","pubTime":"2024-04-26 23:33","pubTimestamp":1714145636,"startTime":"0","endTime":"0","summary":"Shares of AstraZeneca reached new all-time highs this week despite difficult market conditions in the last two months.The revenue and EPS beats were driven by the strong performance of all key growth ","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1437627078/image_1437627078.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1437627078/image_1437627078.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4686685-astrazeneca-strong-in-a-weak-market","is_publish_highlight":false,"gpt_icon":0},{"id":"2430772209","title":"BeiGene Demonstrates Global Progress in 2023 Responsible Business & Sustainability Report","url":"https://stock-news.laohu8.com/highlight/detail?id=2430772209","media":"Business Wire","top":-1,"share":"https://ttm.financial/m/news/2430772209?lang=en_us&edition=fundamental","pubTime":"2024-04-26 22:34","pubTimestamp":1714142040,"startTime":"0","endTime":"0","summary":"Newly released report details Company’s achievements and plans for sustainable growth. BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass., April 26, 2024----BeiGene, Ltd. , a global oncology company, released its 2023 Responsible Business & Sustainability Report highlighting the Company’s strategy, the progress it has made towards existing goals, and how it intends to achieve its bold new targets.This report comes at a time of tremendous growth for BeiGene. In 2023, the Company achieved the milestone of more than 1 million patients who were treated worldwide with BTK inhibitor BRUKINSA  and anti-PD-1 antibody TEVIMBRA . The Company is also actively expanding its presence globally, including in the U.S., where it expects to open a flagship research and development and manufacturing facility at the Princeton West Innovation Campus in Hopewell, New Jersey, in July.BeiGene’s Responsible Business & Sustainability strategy is centered around four pillars: Advancing Global Health, Empowering Our","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/_RzK1Z2WnM7fDBuWpRWvQQ--~B/aD0zMTA7dz0xNjUwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/432051bc0065af629c7ce8bc068e1754","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/_RzK1Z2WnM7fDBuWpRWvQQ--~B/aD0zMTA7dz0xNjUwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/432051bc0065af629c7ce8bc068e1754"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/beigene-demonstrates-global-progress-2023-143400811.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2430509692","title":"These Are The Biotechs Showing Up At The Biggest Cancer Meeting Of The Year (Oral Presentations)","url":"https://stock-news.laohu8.com/highlight/detail?id=2430509692","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2430509692?lang=en_us&edition=fundamental","pubTime":"2024-04-26 05:49","pubTimestamp":1714081756,"startTime":"0","endTime":"0","summary":"The Annual Meeting of the American Society of Clinical Oncology is a major event for clinicians and researchers in the field of oncology.The plenary session will feature presentations on topics such a","market":"us","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1482998631/image_1482998631.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1482998631/image_1482998631.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4686392-these-are-the-biotechs-showing-up-at-the-biggest-cancer-meeting-of-the-year-oral-presentations","is_publish_highlight":false,"gpt_icon":0},{"id":"2430838272","title":"20 Countries with the Highest Rates of Stomach Cancer in the World","url":"https://stock-news.laohu8.com/highlight/detail?id=2430838272","media":"Insider Monkey","top":-1,"share":"https://ttm.financial/m/news/2430838272?lang=en_us&edition=fundamental","pubTime":"2024-04-25 20:53","pubTimestamp":1714049632,"startTime":"0","endTime":"0","summary":"In this article, we will be taking a look at the 20 countries with the highest rates of stomach cancer in the world. If you do not want to learn about the global cancer trends, head straight to the 5 Countries with the Highest Rates of Stomach Cancer in the World.Overview of the Global Stomach Cancer Treatment Market. The global stomach cancer treatment market was valued at $2.61 billion in 2018 and is expected to reach $20.92 billion by 2032, with a noteworthy compounding annual growth rate  of 16% over the forecast period. With over a million cases reported globally in 2020, stomach cancer is thefourth leading cause of cancer deathwith approximately 800,000 deaths in the same year.Although the United States has seen a significant29%decrease in cancer-related mortality since 1991, mostly due to a rise in the use of cancer medications, Europe offers an advantageous market, as both the number of cancer diagnoses and deaths are rising there. On the other hand, cancer patients all over th","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/lt6bvnf.f3_HlFTwQhPiEA--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/1da4007264be4ef25473da75f4099ab8","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/lt6bvnf.f3_HlFTwQhPiEA--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/1da4007264be4ef25473da75f4099ab8"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/20-countries-highest-rates-stomach-125352684.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2430422029","title":"BeiGene (BGNE) Receives a Hold from Bernstein","url":"https://stock-news.laohu8.com/highlight/detail?id=2430422029","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2430422029?lang=en_us&edition=fundamental","pubTime":"2024-04-25 15:45","pubTimestamp":1714031135,"startTime":"0","endTime":"0","summary":"Bernstein analyst Rebecca Liang maintained a Hold rating on BeiGene (BGNE – Research Report) today and set a price target of $152.00. The company’s...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/beigene-bgne-receives-a-hold-from-bernstein?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/beigene-bgne-receives-a-hold-from-bernstein?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2430498623","title":"Global Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2430498623","media":"StreetInsider","top":-1,"share":"https://ttm.financial/m/news/2430498623?lang=en_us&edition=fundamental","pubTime":"2024-04-25 04:01","pubTimestamp":1713988860,"startTime":"0","endTime":"0","summary":"Multiple presentations to showcase the efficacy and safety of BRUKINSA across a range of B-cell malignancies. Company to present three-year data from RATIONALE-306 study of TEVIMBRA in advanced or metastatic esophageal squamous cell carcinoma . “Our data at ASCO are a testament to the potential versatility of TEVIMBRA across a range of tumor types, and we are excited by the momentum of this critical pillar of our solid tumor development program,” said Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeiGene. “During the meeting, we look forward to sharing a new analysis from our RATIONALE-306 study, which will provide insights into the three-year efficacy and safety of TEVIMBRA as a first-line treatment for ESCC.”","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.streetinsider.com/dr/news.php?id=23110649","is_publish_highlight":false,"gpt_icon":0},{"id":"2429116810","title":"BeiGene Shares Rise 7% After European Approval of Tislelizumab Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2429116810","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2429116810?lang=en_us&edition=fundamental","pubTime":"2024-04-23 22:43","pubTimestamp":1713883380,"startTime":"0","endTime":"0","summary":"BeiGene shares were up 7% to $139.39 after the company said the European Commission has approved tislelizumab as a treatment for non-small cell lung cancer across multiple tumor types.The approved indications for tislelizumab are, in combination with carboplatin and either paclitaxel or nab-paclitaxel, for the first-line treatment of adult patients with squamous non-small cell lung cancer. It also can be used as monotherapy for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer after prior platinum-based therapy.BeiGene plans to combine the non-small cell lung cancer indications with the second-line indication under the brand name Tevimbra, which will launch in the first EU countries later in 2024. Tevimbra is approved in the U.S. and EU after prior chemotherapy.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2429130371","title":"With 42% ownership of the shares, BeiGene, Ltd. (NASDAQ:BGNE) is heavily dominated by institutional owners","url":"https://stock-news.laohu8.com/highlight/detail?id=2429130371","media":"Simply Wall St.","top":-1,"share":"https://ttm.financial/m/news/2429130371?lang=en_us&edition=fundamental","pubTime":"2024-04-23 21:49","pubTimestamp":1713880178,"startTime":"0","endTime":"0","summary":"Significantly high institutional ownership implies BeiGene's stock price is sensitive to their trading actions. A total of 5 investors have a majority stake in the company with 52% ownership. A look at the shareholders of BeiGene, Ltd.  can tell us which group is most powerful. And the group that holds the biggest piece of the pie are institutions with 42% ownership. That is, the group stands to benefit the most if the stock rises .Given the vast amount of money and research capacities at their disposal, institutional ownership tends to carry a lot of weight, especially with individual investors. Hence, having a considerable amount of institutional money invested in a company is often regarded as a desirable trait.In the chart below, we zoom in on the different ownership groups of BeiGene.Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.Researching institut","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/42-ownership-shares-beigene-ltd-134938037.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2429164483","title":"BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2429164483","media":"Business Wire","top":-1,"share":"https://ttm.financial/m/news/2429164483?lang=en_us&edition=fundamental","pubTime":"2024-04-23 18:00","pubTimestamp":1713866400,"startTime":"0","endTime":"0","summary":"Comprehensive development program, including three Phase 3 clinical trials, demonstrated benefit of tislelizumab for patients with treatment-nave and relapsed NSCLC. Decision represents tislelizumab’s second approval in the region. In combination with carboplatin and either paclitaxel or nab-paclitaxel for the first-line treatment of adult patients with squamous NSCLC who have locally advanced NSCLC and are not candidates for surgical resection or platinum-based chemoradiation, or metastatic NSCLC.As monotherapy for the treatment of adult patients with locally advanced or metastatic NSCLC after prior platinum-based therapy. Patients with EGFR mutant or ALK positive NSCLC should also have received targeted therapies before receiving tislelizumab.Tislelizumab was approved for these NSCLC indications under the brand name TIZVENI. BeiGene plans to combine the NSCLC indications with the second-line ESCC indication under the brand name TEVIMBRA, which will launch in the first EU countries","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/EMxperUDeWlaHHFp9WTnWA--~B/aD0zMTA7dz0xNjUwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/b98352fb5baedc25bc941447809c124c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/EMxperUDeWlaHHFp9WTnWA--~B/aD0zMTA7dz0xNjUwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/b98352fb5baedc25bc941447809c124c"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/beigene-receives-european-commission-approval-100000832.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2429934262","title":"Is BeiGene (NASDAQ:BGNE) Using Too Much Debt?","url":"https://stock-news.laohu8.com/highlight/detail?id=2429934262","media":"Simply Wall St.","top":-1,"share":"https://ttm.financial/m/news/2429934262?lang=en_us&edition=fundamental","pubTime":"2024-04-21 22:53","pubTimestamp":1713711232,"startTime":"0","endTime":"0","summary":"Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bgne/beigene/news/is-beigene-nasdaqbgne-using-too-much-debt","is_publish_highlight":false,"gpt_icon":0},{"id":"2424271284","title":"BeiGene, Ltd. (NASDAQ:BGNE) is largely controlled by institutional shareholders who own 41% of the company","url":"https://stock-news.laohu8.com/highlight/detail?id=2424271284","media":"Simply Wall St.","top":-1,"share":"https://ttm.financial/m/news/2424271284?lang=en_us&edition=fundamental","pubTime":"2024-03-31 22:52","pubTimestamp":1711896755,"startTime":"0","endTime":"0","summary":"Key Insights Given the large stake in the stock by institutions, BeiGene's stock price might be vulnerable to their...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bgne/beigene/news/beigene-ltd-nasdaqbgne-is-largely-controlled-by-institutiona","is_publish_highlight":false,"gpt_icon":0},{"id":"2423285914","title":"Clear Harbor Asset Management LLC Purchases Shares of 1155 BeiGene, Ltd. (NASDAQ:BGNE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2423285914","media":"Defense World","top":-1,"share":"https://ttm.financial/m/news/2423285914?lang=en_us&edition=fundamental","pubTime":"2024-03-30 19:03","pubTimestamp":1711796617,"startTime":"0","endTime":"0","summary":"Clear Harbor Asset Management LLC Purchases Shares of 1155 BeiGene, Ltd. (NASDAQ:BGNE)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"redbox_crawler","url":"https://news.google.com/rss/articles/CBMifmh0dHBzOi8vd3d3LmRlZmVuc2V3b3JsZC5uZXQvMjAyNC8wMy8zMC9jbGVhci1oYXJib3ItYXNzZXQtbWFuYWdlbWVudC1sbGMtcHVyY2hhc2VzLXNoYXJlcy1vZi0xMTU1LWJlaWdlbmUtbHRkLW5hc2RhcWJnbmUuaHRtbNIBAA?oc=5","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://news.google.com/rss/articles/CBMifmh0dHBzOi8vd3d3LmRlZmVuc2V3b3JsZC5uZXQvMjAyNC8wMy8zMC9jbGVhci1oYXJib3ItYXNzZXQtbWFuYWdlbWVudC1sbGMtcHVyY2hhc2VzLXNoYXJlcy1vZi0xMTU1LWJlaWdlbmUtbHRkLW5hc2RhcWJnbmUuaHRtbNIBAA?oc=5","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.beigene.cn","stockEarnings":[{"period":"1week","weight":-0.0069},{"period":"1month","weight":0.0759},{"period":"3month","weight":0.0963},{"period":"6month","weight":-0.1907},{"period":"1year","weight":-0.3413},{"period":"ytd","weight":-0.1066}],"compareEarnings":[{"period":"1week","weight":0.0187},{"period":"1month","weight":0.0131},{"period":"3month","weight":0.0392},{"period":"6month","weight":0.1821},{"period":"1year","weight":0.2638},{"period":"ytd","weight":0.0958}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The Company has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. It also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.062331},{"month":2,"riseRate":0.625,"avgChangeRate":0.017001},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.028933},{"month":4,"riseRate":0.444444,"avgChangeRate":0.028699},{"month":5,"riseRate":0.555556,"avgChangeRate":-0.006266},{"month":6,"riseRate":0.625,"avgChangeRate":0.022561},{"month":7,"riseRate":0.75,"avgChangeRate":0.132564},{"month":8,"riseRate":0.5,"avgChangeRate":0.021799},{"month":9,"riseRate":0.5,"avgChangeRate":0.051436},{"month":10,"riseRate":0.625,"avgChangeRate":0.017618},{"month":11,"riseRate":0.5,"avgChangeRate":0.059889},{"month":12,"riseRate":0.375,"avgChangeRate":-0.023463}],"exchange":"NASDAQ","name":"BeiGene","nameEN":"BeiGene"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"BeiGene(BGNE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest BeiGene(BGNE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"BeiGene,BGNE,BeiGene股票,BeiGene股票老虎,BeiGene股票老虎国际,BeiGene行情,BeiGene股票行情,BeiGene股价,BeiGene股市,BeiGene股票价格,BeiGene股票交易,BeiGene股票购买,BeiGene股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"BeiGene(BGNE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest BeiGene(BGNE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}